CFO
AMRX icon

CVA Family Office’s Amneal Pharmaceuticals AMRX Stock Holding History

CVA Family Office’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5K Buy
260
+227
+688% +$3.11K ﹤0.01% 1306
2026
Q1 		$410 Buy
+33
New +$443 ﹤0.01% 1773

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

CVA Family Office's AMRX Position: Q2 2026 in Review

CVA Family Office increased its Amneal Pharmaceuticals (AMRX) stake by 688% in Q2 2026, buying an estimated $3.11K and bringing the position to 260 shares worth $4.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

CVA Family Office first reported a position in AMRX in Q1 2026 and has held it in 2 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • CVA Family Office held 260 shares of Amneal Pharmaceuticals worth $4.5K as of Q2 2026.
  • CVA Family Office bought 227 Amneal Pharmaceuticals shares in Q2 2026, an estimated $3.11K.
  • Amneal Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1306 holding.
  • CVA Family Office first reported a position in Amneal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.